Response to Letter to the Editor From Kawaguchi: "Cardiovascular Safety of Romosozumab vs PTH Analogs for Osteoporosis Treatment: A Propensity Score Matched Cohort Study"

J Clin Endocrinol Metab. 2024 Sep 16;109(10):e1978-e1979. doi: 10.1210/clinem/dgae348.
No abstract available

Publication types

  • Letter
  • Editorial
  • Comment

MeSH terms

  • Antibodies, Monoclonal* / adverse effects
  • Antibodies, Monoclonal* / therapeutic use
  • Bone Density Conservation Agents / adverse effects
  • Bone Density Conservation Agents / therapeutic use
  • Cardiovascular Diseases / drug therapy
  • Cohort Studies
  • Humans
  • Osteoporosis* / drug therapy
  • Parathyroid Hormone / blood
  • Propensity Score

Substances

  • romosozumab
  • Antibodies, Monoclonal
  • Bone Density Conservation Agents
  • Parathyroid Hormone